🚀 VC round data is live in beta, check it out!
Rallybio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Rallybio and similar public comparables like Mira Pharmaceuticals, Telomir Pharmaceuticals, Werewolf Therapeutics, Atossa Therapeutics and more.
Rallybio Overview
About Rallybio
Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders.
Founded
2020
HQ
Employees
25
Website
Sectors
Financials (LTM)
Market Cap
$43M
Rallybio Financials
Rallybio reported last 12-month revenue of $508K.
In the same LTM period, Rallybio generated had net loss of ($15M).
Revenue (LTM)
Rallybio P&L
In the most recent fiscal year, Rallybio reported revenue of $858K and EBITDA of ($33M).
Rallybio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $508K | XXX | $858K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($33M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3843%) | XXX | XXX | XXX |
| EBIT Margin | (6474%) | XXX | (3854%) | XXX | XXX | XXX |
| Net Profit | ($15M) | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | (3046%) | XXX | (1046%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Rallybio Stock Performance
Rallybio has current market cap of $43M.
Market Cap Evolution
Rallybio's stock price is $8.21.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $43M | -0.5% | XXX | XXX | XXX | $-1.70 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRallybio Valuation Multiples
Rallybio trades at (21.9x) EV/Revenue multiple, and 0.3x EV/EBITDA.
EV / Revenue (LTM)
Rallybio Financial Valuation Multiples
As of April 11, 2026, Rallybio has market cap of $43M.
Equity research analysts estimate Rallybio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rallybio has a P/E ratio of (2.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV (current) | ($11M) | XXX | ($11M) | XXX | XXX | XXX |
| EV/Revenue | (21.9x) | XXX | (13.0x) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| P/E | (2.8x) | XXX | (4.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Rallybio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Rallybio Margins & Growth Rates
Rallybio's revenue in the last 12 month declined by (100%).
Rallybio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.
Rallybio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3843%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (45%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1670% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3720% | XXX | 2331% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 3954% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Rallybio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mira Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Telomir Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Werewolf Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Atossa Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rein Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rallybio M&A Activity
Rallybio acquired XXX companies to date.
Last acquisition by Rallybio was on XXXXXXXX, XXXXX. Rallybio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Rallybio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRallybio Investment Activity
Rallybio invested in XXX companies to date.
Rallybio made its latest investment on XXXXXXXX, XXXXX. Rallybio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Rallybio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Rallybio
| When was Rallybio founded? | Rallybio was founded in 2020. |
| Where is Rallybio headquartered? | Rallybio is headquartered in United States. |
| How many employees does Rallybio have? | As of today, Rallybio has over 25 employees. |
| Who is the CEO of Rallybio? | Rallybio's CEO is Stephen Uden. |
| Is Rallybio publicly listed? | Yes, Rallybio is a public company listed on Nasdaq. |
| What is the stock symbol of Rallybio? | Rallybio trades under RLYB ticker. |
| When did Rallybio go public? | Rallybio went public in 2021. |
| Who are competitors of Rallybio? | Rallybio main competitors are Mira Pharmaceuticals, Telomir Pharmaceuticals, Werewolf Therapeutics, Atossa Therapeutics. |
| What is the current market cap of Rallybio? | Rallybio's current market cap is $43M. |
| What is the current revenue of Rallybio? | Rallybio's last 12 months revenue is $508K. |
| What is the current revenue growth of Rallybio? | Rallybio revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Rallybio? | Current revenue multiple of Rallybio is (21.9x). |
| Is Rallybio profitable? | No, Rallybio is not profitable. |
| What is the current net income of Rallybio? | Rallybio's last 12 months net income is ($15M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.